|
DE3303707A1
(de)
|
1983-02-04 |
1984-08-09 |
Dynamit Nobel Ag, 5210 Troisdorf |
Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
|
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
|
JPH01167840A
(ja)
|
1987-12-24 |
1989-07-03 |
Konica Corp |
新規な写真用シアンカプラー
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
GB9226855D0
(en)
|
1992-12-23 |
1993-02-17 |
Erba Carlo Spa |
Vinylene-azaindole derivatives and process for their preparation
|
|
US6326469B1
(en)
|
1994-04-22 |
2001-12-04 |
Sugen, Inc. |
Megakaryocytic protein tyrosine kinases
|
|
US5593997A
(en)
|
1995-05-23 |
1997-01-14 |
Pfizer Inc. |
4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
|
|
CH690773A5
(de)
|
1996-02-01 |
2001-01-15 |
Novartis Ag |
Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
|
|
AU3176297A
(en)
|
1996-06-25 |
1998-01-14 |
Novartis Ag |
Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
|
|
TR199902301T2
(xx)
|
1997-03-19 |
1999-12-21 |
Basf Aktiengesellschaft |
Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
|
|
DK0901786T3
(da)
*
|
1997-08-11 |
2007-10-08 |
Pfizer Prod Inc |
Faste farmaceutiske dispersioner med foröget biotilgængelighed
|
|
EP1039909B1
(en)
*
|
1997-12-31 |
2002-10-09 |
Choongwae Pharma Corporation |
Method of production and composition of an oral preparation of itraconazole
|
|
US6303652B1
(en)
|
1998-08-21 |
2001-10-16 |
Hughes Institute |
BTK inhibitors and methods for their identification and use
|
|
WO1999054286A2
(en)
|
1998-04-17 |
1999-10-28 |
Parker Hughes Institute |
Btk inhibitors and methods for their identification and use
|
|
US6998233B2
(en)
|
1998-06-26 |
2006-02-14 |
Sunesis Pharmaceuticals, Inc. |
Methods for ligand discovery
|
|
US20050287596A9
(en)
|
1998-06-26 |
2005-12-29 |
Braisted Andrew C |
Novel ligands and libraries of ligands
|
|
US6335155B1
(en)
|
1998-06-26 |
2002-01-01 |
Sunesis Pharmaceuticals, Inc. |
Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
|
|
UA74141C2
(uk)
|
1998-12-09 |
2005-11-15 |
Дж.Д. Сірл Енд Ко. |
Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
|
|
EP1027886B1
(en)
*
|
1999-02-10 |
2008-07-09 |
Pfizer Products Inc. |
Pharmaceutical solid dispersions
|
|
US6306897B1
(en)
|
1999-03-19 |
2001-10-23 |
Parker Hughes Institute |
Calanolides for inhibiting BTK
|
|
KR20020088406A
(ko)
|
1999-09-17 |
2002-11-27 |
애보트 게엠베하 운트 콤파니 카게 |
치료제로서의 피라졸로피리미딘
|
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
|
ATE277044T1
(de)
|
1999-10-06 |
2004-10-15 |
Boehringer Ingelheim Pharma |
Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
|
|
US6506769B2
(en)
|
1999-10-06 |
2003-01-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
|
JP2003516351A
(ja)
|
1999-11-30 |
2003-05-13 |
パーカー ヒューズ インスティテュート |
コラーゲン誘導血小板凝集阻害剤
|
|
JP2003532632A
(ja)
|
1999-12-17 |
2003-11-05 |
アライアッド・ファーマシューティカルズ・インコーポレーテッド |
新規の複素環
|
|
GB0005345D0
(en)
|
2000-03-06 |
2000-04-26 |
Mathilda & Terence Kennedy Ins |
Methods of treating sepsis septic shock and inflammation
|
|
GB0108903D0
(en)
|
2000-10-05 |
2001-05-30 |
Aventis Pharm Prod Inc |
Novel crystalline forms of a factor Xa inhibitor
|
|
CA2426508A1
(en)
|
2000-10-23 |
2002-05-16 |
Bristol-Myers Squibb Company |
Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
|
|
WO2002045684A2
(en)
|
2000-12-06 |
2002-06-13 |
Pharmacia Corporation |
Rapidly dispersing pharmaceutical composition comprising effervescent agents
|
|
ATE307571T1
(de)
*
|
2001-02-27 |
2005-11-15 |
|
Pharmazeutische formulierung enthaltend bicalutamid
|
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
|
US8306897B2
(en)
|
2001-05-04 |
2012-11-06 |
Stockshield, Inc. |
Method and system for insuring against investment loss
|
|
EP1463742A4
(en)
|
2001-06-21 |
2006-05-10 |
Ariad Pharma Inc |
NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
|
|
CN1523991A
(zh)
|
2001-08-10 |
2004-08-25 |
��˹��ŵ�� |
单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
|
|
EP1425577A4
(en)
|
2001-08-10 |
2004-12-29 |
Symyx Technologies Inc |
APPARATUSES AND METHODS FOR PREPARING AND TESTING PRE-FORMULATIONS AND CORRESPONDING SYSTEMS
|
|
WO2003016338A1
(en)
|
2001-08-15 |
2003-02-27 |
Parker Hughes Institute |
Crystal structure of the btk kinase domain
|
|
NZ532579A
(en)
|
2001-11-21 |
2006-11-30 |
Sunesis Pharmaceuticals Inc |
Methods for ligand discovery based on tethering process
|
|
US20050084905A1
(en)
|
2002-03-21 |
2005-04-21 |
Prescott John C. |
Identification of kinase inhibitors
|
|
GB2388594A
(en)
|
2002-05-16 |
2003-11-19 |
Bayer Ag |
Imidazo-triazine PDE 4 inhibitors
|
|
EP1529046A1
(en)
|
2002-08-08 |
2005-05-11 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Substituted benzimidazole compounds
|
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US7687506B2
(en)
|
2003-04-11 |
2010-03-30 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
|
WO2004100868A2
(en)
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Method of treating transplant rejection
|
|
EP1473039A1
(en)
|
2003-05-02 |
2004-11-03 |
Centre National De La Recherche Scientifique (Cnrs) |
Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
|
|
WO2005014599A1
(en)
|
2003-06-04 |
2005-02-17 |
Cellular Genomics, Inc. |
Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
|
|
WO2005005429A1
(en)
|
2003-06-30 |
2005-01-20 |
Cellular Genomics, Inc. |
Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
|
|
US8591946B2
(en)
*
|
2003-08-29 |
2013-11-26 |
Veloxis Pharmaceuticals A/S |
Modified release compositions comprising tacrolimus
|
|
US8131475B2
(en)
|
2003-09-03 |
2012-03-06 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods for identifying, diagnosing, and predicting survival of lymphomas
|
|
CN1897950A
(zh)
|
2003-10-14 |
2007-01-17 |
惠氏公司 |
稠合芳基和杂芳基衍生物及其使用方法
|
|
ES2372694T3
(es)
|
2003-10-15 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
|
|
AU2003297904A1
(en)
|
2003-12-12 |
2005-07-14 |
University Of Maryland, Baltimore |
Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain
|
|
US20050153990A1
(en)
|
2003-12-22 |
2005-07-14 |
Watkins William J. |
Phosphonate substituted kinase inhibitors
|
|
BRPI0418031A
(pt)
|
2003-12-22 |
2007-04-17 |
Gilead Sciences Inc |
inibidores de quinase fosfonato-substituìdos
|
|
WO2005095406A1
(en)
|
2004-01-26 |
2005-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
CA2553724A1
(en)
|
2004-02-03 |
2005-08-18 |
Abbott Laboratories |
Aminobenzoxazoles as therapeutic agents
|
|
ITMI20041314A1
(it)
|
2004-06-30 |
2004-09-30 |
Nuvera Fuel Cells Europ Srl |
Dispositivo di raffreddamento per celle a combustibili a membrana
|
|
AR053090A1
(es)
|
2004-07-20 |
2007-04-25 |
Osi Pharm Inc |
Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
|
|
US20060079494A1
(en)
|
2004-09-27 |
2006-04-13 |
Santi Daniel V |
Specific kinase inhibitors
|
|
EP1802602A1
(en)
|
2004-09-28 |
2007-07-04 |
Janssen Pharmaceutica N.V. |
Substituted dipiperdine ccr2 antagonists
|
|
EP1812442A2
(en)
|
2004-11-10 |
2007-08-01 |
CGI Pharmaceuticals, Inc. |
Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
|
|
GB0425035D0
(en)
|
2004-11-12 |
2004-12-15 |
Novartis Ag |
Organic compounds
|
|
KR101335932B1
(ko)
|
2005-03-07 |
2013-12-04 |
바이엘 헬스케어 엘엘씨 |
암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
|
|
WO2006099075A2
(en)
|
2005-03-10 |
2006-09-21 |
Cgi Pharmaceuticals, Inc. |
Certain substituted amides, method of making, and method of use thereof
|
|
DE602006019088D1
(de)
|
2005-05-13 |
2011-02-03 |
Irm Llc |
Verbindungen und zusammensetzungen als proteinkinase-hemmer
|
|
DK2395004T3
(en)
|
2005-06-22 |
2016-03-21 |
Plexxikon Inc |
Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
|
|
US20070065449A1
(en)
|
2005-09-16 |
2007-03-22 |
Claire Verschraegen |
Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
|
|
WO2007058832A2
(en)
|
2005-11-12 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
|
|
BRPI0621027A2
(pt)
|
2006-01-13 |
2011-11-29 |
Pharmacyclics Inc |
composto, composição farmacêutica
|
|
EP1984030B1
(en)
|
2006-01-30 |
2013-05-08 |
The Scripps Research Institute |
Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
|
|
WO2007109604A2
(en)
*
|
2006-03-20 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
|
EA200870409A1
(ru)
|
2006-04-04 |
2009-04-28 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Антагонисты киназы pi3
|
|
AU2007254179B2
(en)
|
2006-05-18 |
2013-03-21 |
Pharmacyclics Llc |
Intracellular kinase inhibitors
|
|
DE102006026583A1
(de)
|
2006-06-07 |
2007-12-13 |
Bayer Healthcare Aktiengesellschaft |
Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
|
|
PL2526933T3
(pl)
|
2006-09-22 |
2015-08-31 |
Pharmacyclics Llc |
Inhibitory kinazy tyrozynowej Brutona
|
|
ES2403546T3
(es)
|
2006-11-03 |
2013-05-20 |
Pharmacyclics, Inc. |
Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
|
|
NL2000640C2
(nl)
|
2007-03-05 |
2008-09-08 |
Stichting Wetsus Ct Of Excelle |
Werkwijze en systeem voor het zuiveren van een vloeistof.
|
|
US20120101113A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
SG10201508035TA
(en)
|
2007-03-28 |
2015-10-29 |
Pharmacyclics Inc |
Inhibitors of bruton's tyrosine kinase
|
|
US20120065201A1
(en)
|
2007-03-28 |
2012-03-15 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
US20090010911A1
(en)
|
2007-04-06 |
2009-01-08 |
Iowa State University Research Foundation, Inc. |
Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
|
|
US7982036B2
(en)
|
2007-10-19 |
2011-07-19 |
Avila Therapeutics, Inc. |
4,6-disubstitued pyrimidines useful as kinase inhibitors
|
|
JP5587193B2
(ja)
|
2007-10-23 |
2014-09-10 |
エフ．ホフマン−ラ ロシュ アーゲー |
新規なキナーゼ阻害剤
|
|
US8426441B2
(en)
|
2007-12-14 |
2013-04-23 |
Roche Palo Alto Llc |
Inhibitors of bruton's tyrosine kinase
|
|
US20150152115A1
(en)
|
2007-12-27 |
2015-06-04 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
JP5714910B2
(ja)
|
2008-01-09 |
2015-05-07 |
チャールストン ラボラトリーズ，インコーポレイテッド |
薬学的組成物
|
|
US8808742B2
(en)
|
2008-04-14 |
2014-08-19 |
Ardea Biosciences, Inc. |
Compositions and methods for preparing and using same
|
|
EP2123626A1
(en)
|
2008-05-21 |
2009-11-25 |
Laboratorios del Dr. Esteve S.A. |
Co-crystals of duloxetine and co-crystal formers for the treatment of pain
|
|
NZ603525A
(en)
|
2008-06-27 |
2015-02-27 |
Celgene Avilomics Res Inc |
Pyrimidine based compound and uses thereof
|
|
CA2730930C
(en)
|
2008-07-16 |
2015-01-13 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
|
JP2012504553A
(ja)
|
2008-07-29 |
2012-02-23 |
フロンティア サイエンティフィック インコーポレイテッド |
微生物の殺滅または増殖抑制のためのテトラキス（ｎ−アルキルピリジニウム）−ポルフィリン誘導体の使用
|
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
WO2010068806A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
|
|
WO2010126960A1
(en)
|
2009-04-29 |
2010-11-04 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
|
US9556426B2
(en)
|
2009-09-16 |
2017-01-31 |
Celgene Avilomics Research, Inc. |
Protein kinase conjugates and inhibitors
|
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
|
MX2012013622A
(es)
|
2010-05-31 |
2013-02-01 |
Ono Pharmaceutical Co |
Derivado de purinona.
|
|
NZ772688A
(en)
|
2010-06-03 |
2022-09-30 |
Pharmacyclics Llc |
The use of inhibitors of bruton’s tyrosine kinase (btk)
|
|
US20120071497A1
(en)
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
|
CA2803056C
(en)
|
2010-06-23 |
2017-05-16 |
Hanmi Science Co., Ltd. |
Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
|
|
CN105566229A
(zh)
|
2010-08-10 |
2016-05-11 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐及其用途和制备方法
|
|
US8541391B2
(en)
|
2010-10-28 |
2013-09-24 |
Viropharma Incorporated |
Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
|
|
US8501484B2
(en)
|
2011-03-14 |
2013-08-06 |
Los Alamos National Security, Llc |
Preparation of cerium halide solvate complexes
|
|
MX2011004759A
(es)
|
2011-05-04 |
2012-11-21 |
Senosiain S A De C V Lab |
Nuevas formas solidas de antibioticos.
|
|
EA025496B1
(ru)
|
2011-05-17 |
2016-12-30 |
Принсипиа Биофарма Инк. |
Ингибиторы тирозинкиназы
|
|
CN103813794A
(zh)
|
2011-07-18 |
2014-05-21 |
拓凯制药公司 |
用于治疗前列腺癌的新型组合物及方法
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
DK3181122T3
(da)
*
|
2012-01-13 |
2023-06-06 |
Xspray Pharma Ab Publ |
Farmaceutisk dasatinib-sammensætning
|
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
|
JP5514256B2
(ja)
|
2012-05-18 |
2014-06-04 |
株式会社東芝 |
磁気記憶素子及びその製造方法
|
|
WO2013184572A1
(en)
|
2012-06-04 |
2013-12-12 |
Pharmacyclics, Inc. |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
|
DK2861599T3
(da)
|
2012-06-18 |
2020-03-02 |
Principia Biopharma Inc |
Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
|
|
WO2014004707A1
(en)
|
2012-06-29 |
2014-01-03 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
|
AU2013293087B2
(en)
|
2012-07-24 |
2017-08-31 |
Pharmacyclics Llc |
Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
|
|
CN103121999A
(zh)
|
2012-08-29 |
2013-05-29 |
苏州迪飞医药科技有限公司 |
一种酪氨酸激酶抑制剂pci-32765的合成方法
|
|
SG11201503842PA
(en)
|
2012-11-15 |
2015-06-29 |
Pharmacyclics Inc |
Pyrrolopyrimidine compounds as kinase inhibitors
|
|
ES2834638T3
(es)
|
2013-05-30 |
2021-06-18 |
Infinity Pharmaceuticals Inc |
Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa
|
|
US20160067241A1
(en)
|
2013-06-13 |
2016-03-10 |
Dennis M. Brown |
Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
|
|
US9421208B2
(en)
|
2013-08-02 |
2016-08-23 |
Pharmacyclics Llc |
Methods for the treatment of solid tumors
|
|
WO2015034478A1
(en)
|
2013-09-04 |
2015-03-12 |
Halliburton Energy Services, Inc. |
Scale-inhibiting cocrystals for treatment of a subterranean formation
|
|
CA3206628A1
(en)
|
2013-09-12 |
2015-03-19 |
Dana-Farber Cancer Institute, Inc. |
Methods for evaluating and treating waldenstrom's macroglobulinemia
|
|
TWI617309B
(zh)
|
2013-10-25 |
2018-03-11 |
製藥公司 |
使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
|
|
WO2015071432A1
(en)
|
2013-11-14 |
2015-05-21 |
Sandoz Ag |
Pharmaceutical compositions of ibrutinib
|
|
CN103694241A
(zh)
|
2013-11-27 |
2014-04-02 |
苏州晶云药物科技有限公司 |
Pci-32765的新晶型a及其制备方法
|
|
US20160310417A1
(en)
|
2013-12-20 |
2016-10-27 |
Emory University |
Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
|
|
CN106008521A
(zh)
|
2014-01-29 |
2016-10-12 |
苏州晶云药物科技有限公司 |
依鲁替尼的新晶型及其制备方法
|
|
WO2015120110A2
(en)
|
2014-02-07 |
2015-08-13 |
Auspex Pharmaceuticals, Inc. |
Novel pharmaceutical formulations
|
|
US20150231077A1
(en)
|
2014-02-17 |
2015-08-20 |
The Cleveland Clinic Foundation |
Amine passivated nanoparticles for cancer treatment and imaging
|
|
WO2015127261A1
(en)
|
2014-02-21 |
2015-08-27 |
Pharmacyclics, Inc. |
Biomarkers for predicting response of dlbcl to treatment with ibrutinib
|
|
US20150267752A1
(en)
|
2014-03-19 |
2015-09-24 |
Roller Bearing Company Of America, Inc. |
Bearing outer race having a radially inwardly biased seal
|
|
CA2942528A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
|
US9884869B2
(en)
|
2014-03-27 |
2018-02-06 |
Perrigo Api Ltd. |
Ibrutinib solid forms and production process therefor
|
|
CN105085529A
(zh)
|
2014-05-15 |
2015-11-25 |
广东东阳光药业有限公司 |
依鲁替尼新晶型及其制备方法
|
|
US9127069B1
(en)
|
2014-06-11 |
2015-09-08 |
Antecip Bioventures LLC |
Compositions comprising rank/rankl antagonists and related compounds for treating pain
|
|
US20150110871A1
(en)
|
2014-06-02 |
2015-04-23 |
David Wong |
Gastric retentive tablet compositions
|
|
US20160008777A1
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting Inc. |
Pharmaceutical compounding kit
|
|
PT107846B
(pt)
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
|
WO2016020697A1
(en)
|
2014-08-06 |
2016-02-11 |
Cipla Limited |
Pharmaceutical compositions of polymeric nanoparticles
|
|
US9545407B2
(en)
|
2014-08-07 |
2017-01-17 |
Pharmacyclics Llc |
Formulations of a bruton's tyrosine kinase inhibitor
|
|
EP3180343A1
(en)
|
2014-08-14 |
2017-06-21 |
Assia Chemical Industries Ltd. |
Solid state forms of ibrutinib
|
|
EP3201197B1
(en)
|
2014-10-01 |
2019-03-27 |
ratiopharm GmbH |
Acid addition salt of ibrutinib
|
|
CN104523695A
(zh)
|
2014-11-12 |
2015-04-22 |
广东东阳光药业有限公司 |
一种治疗过度增生性疾病的药物组合物
|
|
CN105640961A
(zh)
|
2014-11-18 |
2016-06-08 |
山东瑞禾医药科技有限公司 |
一种含依鲁替尼的药物组合物
|
|
WO2016079216A1
(en)
|
2014-11-20 |
2016-05-26 |
Sandoz Ag |
Physical forms of ibrutinib, a bruton's kinase inhibitor
|
|
US20150224060A1
(en)
|
2015-01-03 |
2015-08-13 |
David Wong |
Gastric retentive tablet compositions
|
|
CZ201584A3
(cs)
|
2015-02-09 |
2016-08-17 |
Zentiva, K.S. |
Sůl Ibrutinib sulfátu
|
|
JP2018511580A
(ja)
|
2015-03-03 |
2018-04-26 |
ドクター レディズ ラボラトリーズ リミテッド |
イブルチニブの多形体
|
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
|
|
JP6705833B2
(ja)
|
2015-04-02 |
2020-06-03 |
ラティオファルム ゲー・エム・ベー・ハー |
イブルチニブとカルボン酸との共結晶
|
|
PL3892302T3
(pl)
|
2015-04-06 |
2024-03-11 |
Janssen Pharmaceutica Nv |
Kompozycje zawierające ibrutynib
|
|
CN105294696A
(zh)
|
2015-11-19 |
2016-02-03 |
上海创诺医药集团有限公司 |
依鲁替尼新晶型及其制备方法
|
|
CN105440040B
(zh)
|
2015-12-23 |
2018-03-13 |
浙江京新药业股份有限公司 |
依鲁替尼的纯化方法
|
|
CN105646498A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型f及制备方法
|
|
CN105646499A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型g及制备方法
|
|
CN105646484A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
晶型b及制备方法
|
|
CN106619643A
(zh)
|
2016-11-11 |
2017-05-10 |
上海雅本化学有限公司 |
一种含依鲁替尼的药物组合物
|